CA-ENLIGHTED
16.7.2020 12:02:06 CEST | Business Wire | Press release
Enlighted , the leading building IoT platform provider, expands its award-winning IoT technology with workplace digital contact tracing to help employees return safely to manufacturing facilities, pharmaceutical labs, offices and more. Safe provides digital contact history for employees who self-report testing positive for COVID-19 to help reduce the spread of infection, keep healthy employees safe and productive, and eliminate the tedious, expensive and error-prone manual contact tracing process for employers.
The solution prioritizes data privacy without the need for storing personal information. Employees are assigned alphanumeric ID badges while entering the workplace. When an employee self-reports their badge ID and a positive test result, administrators query the Safe application, identify other IDs this badge came in contact with and share the anonymous IDs. Employees carrying those badge IDs can self-identify their exposure.
The Enlighted solution provides employers with location and proximity data to identify who an infected employee came in contact with inside the workplace, for how long and what areas they visited. The data is used to inform employees who might be at risk of infection and also drives sanitization efforts in areas the infected employee utilized. The application’s dashboard provides information on contacts in the building to assist management in developing safer workplace strategies. Additionally, Safe identifies how many close contacts are happening in a time period and location to proactively manage risk.
Enlighted is in a unique position to provide proven safer workplace solutions for COVID-19 and beyond with its IoT technology already installed in 320 million square feet of buildings globally. Existing customers can simply add the Safe app to their IoT platform. New customers can install the Enlighted IoT system through sensors in LED lighting or through the new USB-powered surface sensor , which can be easily applied under desks or in conference rooms.
“The important role of IoT technology in buildings has been further magnified by the COVID-19 pandemic,” said Stefan Schwab, CEO of Enlighted, a Siemens company. “The Enlighted sensory system can now provide digital contact tracing. It also lays the foundation for future-proofed buildings ready to help us understand with real-time data the changing nature of our at-work experiences and meet challenges beyond COVID-19.”
Enlighted offers a suite of data-driven safer workplace solutions , assisting planners in preparing and executing physical distancing processes, enhanced sanitization and monitoring, occupancy limits and now contact tracing. The IoT platform also integrates through APIs with third-party systems to provide touchless entry, smart desk hoteling, conference room booking and more.
The Safe application is available immediately for new and existing Enlighted customers. Visit www.enlightedinc.com/contact-sales to talk with a sales representative or request a demonstration, or visit http://www.enlightedinc.com to learn about Enlighted’s full suite of workplace safety solutions.
ABOUT ENLIGHTED
Designed to change everything, Enlighted provides the world’s most advanced Building IoT Platform for leading commercial and healthcare organizations around the globe, with more than 320 million square feet of building space deployed to date. Founded in 2009 and headquartered in Silicon Valley, Enlighted was acquired in 2018 and is a wholly-owned subsidiary of Siemens Industry, Inc. as part of Siemens Smart Infrastructure. For more information about Enlighted, visit enlightedinc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom